Cilostazol PCD Pharma Franchise Company
Cafoli Lifecare offers a Cilostazol range of 2 tablet formulations, manufactured in WHO-GMP certified facilities. Distributors serving the vascular and cardiovascular segment can secure district-wise monopoly franchise rights on this specialist antiplatelet molecule.
What is Cilostazol?
Cilostazol is a phosphodiesterase-3 inhibitor with antiplatelet and vasodilatory actions. By raising cyclic AMP it inhibits platelet aggregation and dilates arteries, improving blood flow and walking distance in peripheral artery disease. Compound details are available on PubChem.
Therapeutic Applications
Cilostazol is primarily indicated for intermittent claudication — leg pain on walking due to peripheral artery disease — to increase pain-free walking distance. Prescribers include vascular surgeons, cardiologists, diabetologists and consultant physicians managing diabetic and elderly patients with arterial insufficiency.
Why Cilostazol is a High-Potential Molecule for Distributors
Peripheral artery disease is rising in step with the large and growing diabetic population in India, and cilostazol is the primary evidence-based option for symptomatic claudication. Because demand is specialist-driven and the molecule occupies a defined niche, it faces far less price erosion than mass-market cardiac drugs, letting franchise partners protect margins while building a differentiated vascular line.
Why Choose Cafoli Lifecare
Cafoli Lifecare is a WHO-GMP compliant, DCGI-approved PCD pharma company with 1000+ franchise partners across India. Partners receive district-wise monopoly rights, promotional inputs including visual aids, MR bags and product cards, and consistent stock availability backed by quality-tested manufacturing.
References
- PubChem: Cilostazol
- MedlinePlus: Cilostazol
Our formulations of Cilostazol find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: